Stock Financial Ratios

ACOR / Acorda Therapeutics, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)818.84
Enterprise Value ($M)929.24
Book Value ($M)664.21
Book Value / Share14.68
Price / Book1.20
NCAV ($M)872.48
NCAV / Share19.28
Price / NCAV0.99
Income Statement (mra) ($M)
Net Income-35.60
Balance Sheet (mrq) ($M)
Cash & Equivalents192.50
Cash / Share4.25
Quick Ratio1.62
Current Ratio1.62
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.05
Return on Assets (ROA)-0.04
Return on Equity (ROE)-0.05
Identifiers and Descriptors
Central Index Key (CIK)1008848
Industry Groups
SIC 2836 - Biological Products, Except Diagnostic Substances (Biotech)
Other Related CUSIPS
Share Statistics
Common Shares Outstanding (M)46.75
Scoring Models
Piotroski F Score4.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Kaplan-Zingales KZ-IndexN/A
Cash Conversion CycleN/A
Per Share Metrics
Inventory Work In Progress Per Share0.00
Long Term Debt Per Share0.00
Assets Current Per Share5.82
Debt Per Share0.00
Liabilities And Stock Equity Per Share29.72
Deferred Income Tax Liabilities Per Share0.00
Additional Paid In Capital Per Share21.16
Liabilities Per Share14.69
Property Plant And Equipment Per Share0.81
Cash And Equivalents Per Share4.25
Intangibles Per Share15.58
Accounts Receivable Per Share1.19
Accumulated Depreciation And Depletion Per Share0.00
Goodwill Per Share6.30
Minority Interest Per Share0.00
Current Portion Of Long Term Debt Per Share0.00
Property Plant And Equipment Gross Per Share0.00
Equity Per Share15.02
Inventory Raw Materials Per Share0.00
Liabilities Other Non Current Per Share0.24
Property Plant And Equipment Net Per Share0.81
Cash Per Share4.25
Assets Other Current Per Share0.16
Inventory Finished Goods Per Share0.00
Accounts Payable Per Share0.00
Liabilities Current Per Share2.41
Preferred Stock Value Outstanding Per Share0.00
Assets Non Current Per Share0.00
Assets Per Share22.44
Treasury Stock Per Share0.01
Assets Other Non Current Per Share0.19
Inventory Per Share0.00
Retained Earnings Per Share-6.28

Related News Stories

Acorda Stock Up Despite Phase III Trial on Tozadenant Stops

1h zacks
Acorda Therapeutics, Inc. (ACOR - Free Report) announced that it has decided to immediately discontinue the phase III study on one of its lead Parkinson’s disease (“PD”) candidates, tozadenant. (99-0)

3 Things In Biotech You Should Learn Today: November 21, 2017

10h seekingalpha
Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotechnology research. (15-1)

BRIEF-Acorda discontinues Tozadenant development program

2017-11-20 reuters
* Acorda Therapeutics - ‍decision based on new information obtained from phase 3 program related to previously disclosed agranulocytosis and associated serious adverse events​ (12-0)

Acorda Plunges On Safety Issues For Parkinson's Drug, Short Opportunity Presents Itself

2017-11-18 seekingalpha
Acorda lost in court relating to a majority of Ampyra patents, which means generics competitors could launch as early as mid-2018. (12-1)

ACORDA THERAPEUTICS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Investing In Acorda Therapeutics, Inc. To Contact The Firm

2017-11-17 accesswire
NEW YORK, NY / ACCESSWIRE / November 17, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. ("Acorda" or the "Company") (NASDAQ: ACOR). (27-0)

CUSIP: 00484M106